SGLT2 inhibitors and lower limb complications: an updated meta-analysis.

What the trial testedas reported · 2021

Not counted

1.6×1× to 2.5×

Bigger than 8 in 10 for cardiovascular events

As reported

OR 1.60, 95% CI 1.04–2.46

Not counted

1.5×1.1× to 2×

Bigger than 8 in 10 for cardiovascular events

As reported

OR 1.53, 95% CI 1.14–2.05

the abstract, start to end

… treatment (amputation: OR = 1.60, 95% CI 1.04 to 2.46; PAD: OR = 1.53, 95 % CI 1.14 to 2.05).

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

OR 1.601.04–2.46

Cardiovascular events

OR 1.531.14–2.05

SGLT2 inhibitorsCardiovascular events

1 / 3

2021

2022

2023

2024

2025

2026

this paperpooled itcites it